Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02978417 · ClinicalTrials.gov registry record · Phase 4

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings

A Phase 4 study of Opioid-Related Disorders, sponsored by Duke University.

Completed
Registry status
Phase 4
Development phase
14
Enrollment target
1
Study location

NCT02978417 is a Phase 4 study of Opioid-Related Disorders that has completed, run by Duke University. The registered enrollment target is 14 participants, below the 347-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02978417, a Phase 4 study of Opioid-Related Disorders, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 4
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

In preparation for a large-scale randomized controlled trial (RCT) of Vivitrol® effectiveness in drug courts, investigators propose a feasibility study in the Wake County, North Carolina drug court, where an estimated 50% of clients are opioid dependent. Aim 1: Pilot RCT. Pilot-test the delivery of Vivitrol® treatment for 10-20 interested and eligible clients of the Wake County Drug Court.

Conditions Studied

Interventions

  • DRUG Naltrexone for extended-release injectable suspension
  • DRUG Oral naltrexone

Study Locations (1)

North Carolina

  • Fellowship Health Resources (FHR) - Raleigh

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2017-09-21
Est. Completion 2019-06-30
Phase Phase 4

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT02978417

The ClinicalTrials.gov registry entry for NCT02978417 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 347-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (96% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Naltrexone for extended-release injectable suspension is the first listed.

NCT02978417 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT02978417 about?

NCT02978417 is a clinical study titled "Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings". In preparation for a large-scale randomized controlled trial (RCT) of Vivitrol® effectiveness in drug courts, investigators propose a feasibility study in the Wake County, North Carolina drug court, where an estimated 50% of clients are opioid dependent. Aim 1: Pilot RCT. Pilot-test the delivery of...

What is the current status of trial NCT02978417?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2017-09-21. Estimated completion is 2019-06-30.

What conditions does trial NCT02978417 study?

This clinical trial studies the following conditions: Opioid-Related Disorders.

What interventions are being tested in trial NCT02978417?

The interventions under investigation include: Naltrexone for extended-release injectable suspension (DRUG), Oral naltrexone (DRUG).

Who is sponsoring clinical trial NCT02978417?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02978417 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid-Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.